GU Cancer

PBS listings supported for solid cancer drugs

The Pharmaceutical Benefits Advisory Committee has supported a request to list cabozantinib on the PBS for the treatment of stage IV clear cell variant renal cell carcinoma. The positive PBAC recommendation from a December 2017 meeting was justified on a cost-minimisation basis against nivolumab. “The PBAC considered that cabozantinib had non-inferior efficacy compared to nivolumab ...

Already a member?

Login to keep reading.

© 2021 the limbic